Compare The Coca-Cola Co K (KO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Sana Biotechnology Inc — how do they compare? The Coca-Cola Co K trades at $86.73 (market cap $372.08B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: The Coca-Cola Co K is far larger — about 329.3× Sana Biotechnology Inc's market cap, and The Coca-Cola Co K pays a 2.45% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KO | SANA | |
|---|---|---|
Market Cap | $372.08B | $1.13B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $5.92 |
52-Week Low | $65.67 | $2.68 |
Enterprise Value | $399.26B | $1.05B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.67, down 0.23% on the day, with a bullish technical signal driven by moving averages and strong support at $85. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains high profitability margins, including a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends, while the upcoming Q3 2026 earnings are anticipated at $0.87 EPS.
The stock offers a compelling dividend yield with 64 consecutive years of increases, supported by solid cash flow and a consensus price target of $95.83 implying 10.6% upside. Risks include regional demand volatility in Asia and high debt levels, but analyst sentiment is bullish with 60% buy ratings. Long-term growth prospects remain intact given brand strength and global footprint.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
